Biography
Robert Fletcher is a candidate on the Heath Data Research UK-The Alan Turing Institute Wellcome Trust PhD Programme in Health Data Science. His research focuses on the study of cardio-renal-metabolic conditions in whole-population electronic health records, including both the modern epidemiology and intersection of heart failure and chronic kidney disease, and trends in obesity and its treatment in English adults. Via The George Institute for Global Health, he also serves as Analytics Lead for the SGLT2 Inhibitor Meta-Analysis CardioRenal Trialists Consortium (SMART-C), a public-private partnership that brings together 13 landmark, randomised, placebo-controlled, clinical outcome trials of SGLT2 inhibitors comprising over 90,000 patients with type 2 diabetes, heart failure, and chronic kidney disease.
Research
Obesity, Heart Failure, Chronic Kidney Disease
Publications
Fletcher RA, Rockenschaub P, Neuen BL, Walter IJ, Conrad N, Mizani MA, Bolton T, Lawson CA, Tomlinson C, Logothetis SB, Petitjean C. Contemporary epidemiology of hospitalised heart failure with reduced versus preserved ejection fraction in England: a retrospective, cohort study of whole-population electronic health records. The Lancet Public Health. 2024 Nov 1;9(11):e871-85.
Talbot B, Fletcher RA, Neal B, Oshima M, Adshead F, Moore K, McGain F, McAlister S, Barraclough KA, Knight J, Neuen BL. The potential for reducing greenhouse gas emissions through disease prevention: a secondary analysis of data from the CREDENCE trial. The Lancet Planetary Health. 2024 Dec 1;8(12):e1055-64.
Apperloo EM, Neuen BL, Fletcher RA, Jongs N, Anker SD, Bhatt DL, Butler J, Cherney DZ, Herrington WG, Inzucchi SE, Jardine MJ. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. The Lancet Diabetes & Endocrinology. 2024 Aug 1;12(8):545-57.
Neuen BL, Fletcher RA, Heath L, Perkovic A, Vaduganathan M, Badve SV, Tuttle KR, Pratley R, Gerstein HC, Perkovic V, Heerspink HJ. Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Circulation. 2024 Nov 26;150(22):1781-90.
Neuen BL, Heerspink HJ, Vart P, Claggett BL, Fletcher RA, Arnott C, de Oliveira Costa J, Falster MO, Pearson SA, Mahaffey KW, Neal B. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation. 2024 Feb 6;149(6):450-62.
Fletcher RA, Jongs N, Chertow GM, McMurray JJ, Arnott C, Jardine MJ, Mahaffey KW, Perkovic V, Rockenschaub P, Rossing P, Correa-Rotter R. Effect of SGLT2 Inhibitors on Discontinuation of Renin–angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials. Journal of the American Society of Nephrology. 2023 Nov 22:10-681.
Fletcher RA, Herrington WG, Agarwal R, Mayne KJ, Arnott C, Jardine MJ, Mahaffey KW, Perkovic V, Staplin N, Wheeler DC, Chertow GM. Effects of SGLT2 inhibitors on cause-specific cardiovascular death in patients with chronic kidney disease: a meta-analysis of CKD progression trials. Clinical Journal of the American Society of Nephrology: CJASN. 2024 Apr 16.
Fletcher RA, Arnott C, Rockenschaub P, Schutte AE, Carpenter L, Vaduganathan M, Agarwal R, Bakris G, Chang TI, Heerspink HJ, Jardine MJ. Canagliflozin, blood pressure variability, and risk of cardiovascular, kidney, and mortality outcomes: pooled individual participant data from the CANVAS and CREDENCE trials. Journal of the American Heart Association. 2023 Jul 4;12(13):e028516.
Other Professional Activities
Analytics Lead, the SGLT2 Inhibitor Meta-Analysis CardioRenal Trialists Consortium (SMART-C)
